192 related articles for article (PubMed ID: 16026227)
21. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
Colonna L; Andersen HF; Reines EH
Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
[TBL] [Abstract][Full Text] [Related]
22. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
23. Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
Bech P; Andersen HF; Wade A
Pharmacopsychiatry; 2006 Jul; 39(4):128-34. PubMed ID: 16871468
[TBL] [Abstract][Full Text] [Related]
24. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?
Montgomery SA; Möller HJ
Int Clin Psychopharmacol; 2009 May; 24(3):111-8. PubMed ID: 19357527
[TBL] [Abstract][Full Text] [Related]
25. Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome.
Howland RH; Rush AJ; Wisniewski SR; Trivedi MH; Warden D; Fava M; Davis LL; Balasubramani GK; McGrath PJ; Berman SR
Drug Alcohol Depend; 2009 Jan; 99(1-3):248-60. PubMed ID: 18986774
[TBL] [Abstract][Full Text] [Related]
26. Treatments for generalized anxiety disorder.
Struzik L; Vermani M; Coonerty-Femiano A; Katzman MA
Expert Rev Neurother; 2004 Mar; 4(2):285-94. PubMed ID: 15853570
[TBL] [Abstract][Full Text] [Related]
27. Escitalopram: a review of its use in the management of anxiety disorders.
Dhillon S; Scott LJ; Plosker GL
CNS Drugs; 2006; 20(9):763-90. PubMed ID: 16953656
[TBL] [Abstract][Full Text] [Related]
28. Escitalopram.
Burke WJ
Expert Opin Investig Drugs; 2002 Oct; 11(10):1477-86. PubMed ID: 12387707
[TBL] [Abstract][Full Text] [Related]
29. The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders.
Bareggi SR; Mundo E; Dell'Osso B; Altamura AC
Expert Opin Drug Metab Toxicol; 2007 Oct; 3(5):741-53. PubMed ID: 17916059
[TBL] [Abstract][Full Text] [Related]
30. Mixed anxiety and depression in older adults: clinical characteristics and management.
Cassidy EL; Lauderdale S; Sheikh JI
J Geriatr Psychiatry Neurol; 2005 Jun; 18(2):83-8. PubMed ID: 15911936
[TBL] [Abstract][Full Text] [Related]
31. Generalized anxiety disorder.
Gliatto MF
Am Fam Physician; 2000 Oct; 62(7):1591-600, 1602. PubMed ID: 11037076
[TBL] [Abstract][Full Text] [Related]
32. Use of benzodiazepines in social anxiety disorder, generalized anxiety disorder, and posttraumatic stress disorder.
Davidson JR
J Clin Psychiatry; 2004; 65 Suppl 5():29-33. PubMed ID: 15078116
[TBL] [Abstract][Full Text] [Related]
33. Paroxetine in panic disorder: clinical management and long-term follow-up.
Dannon PN; Lowengrub K; Iancu I; Kotler M
Expert Rev Neurother; 2004 Mar; 4(2):191-8. PubMed ID: 15853560
[TBL] [Abstract][Full Text] [Related]
34. Antidepressants in panic disorder.
Wade AG
Int Clin Psychopharmacol; 1999 May; 14 Suppl 2():S13-7. PubMed ID: 10471168
[TBL] [Abstract][Full Text] [Related]
35. The effect of escitalopram on metabolic parameters in patients with major depressive disorder, generalised anxiety disorder, and panic disorder: a prospective 6-month follow-up study.
Peh AL; Nieng CH; Ling YH; Kheng TW; Neng TS; Koon OG
Asian J Psychiatr; 2013 Jun; 6(3):256-7. PubMed ID: 23642988
[No Abstract] [Full Text] [Related]
36. [Escitalopram--second generation of serotonin transporter inhibitors?].
Rybakowski J; Borkowska AB
Psychiatr Pol; 2004; 38(2):227-39. PubMed ID: 15307289
[TBL] [Abstract][Full Text] [Related]
37. Escitalopram: better treatment for depression is through the looking glass.
Malin P; Wengel SP; Burke WJ
Expert Rev Neurother; 2004 Sep; 4(5):769-79. PubMed ID: 15853504
[TBL] [Abstract][Full Text] [Related]
38. Serotonergic drugs in the treatment of depressive and anxiety disorders.
Den Boer JA; Bosker FJ; Slaap BR
Hum Psychopharmacol; 2000 Jul; 15(5):315-336. PubMed ID: 12404310
[TBL] [Abstract][Full Text] [Related]
39. Managing depressive and anxiety disorders with escitalopram.
Thase ME
Expert Opin Pharmacother; 2006 Mar; 7(4):429-40. PubMed ID: 16503815
[TBL] [Abstract][Full Text] [Related]
40. Influence of anxiety symptoms on improvement of neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study.
Yoo I; Woo JM; Lee SH; Fava M; Mischoulon D; Papakostas GI; Kim EJ; Chung S; Ha JH; Jeon HJ
J Affect Disord; 2015 Oct; 185():24-30. PubMed ID: 26142691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
